IRCT2016092713194N2CompletedPhase 3
The effect of crocin on inflammation factors,DNA damage and biomarkers of oxidative injury in the blood of patients with multiple sclerosis
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 40
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20 years to 40 years (—)
- Sex
- All
Inclusion Criteria
- •inclusion criteria: Recently diagnosed relapsing-remitting MS patients; Patients between 20-40 years old
- •exclusion criteria: Receiving immunomodulatory drugs such as interferons; Diabetes; Chronic disease like cardiac, liver or kidney disease; Smoking; Pregnancy and lactation; EDSS>4; Any rheumatologic disease or vasculitis; History of hypersensitivity to saffron
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Not yet recruiting
Phase 2
Investigating the effect of crocin in multiple sclerosis patientsMultiple sclerosisIRCT20130418013058N17Mashhad University of Medical Sciences40
Not yet recruiting
Phase 2
The effect of crocin in multiple sclerosis patientsMultiple sclerosisCondition 1: Multiple sclerosis. Condition 2: Multiple sclerosis. Condition 3: Multiple sclerosis.Other acute disseminated demyelinationOther demyelinating diseases of central nervous systemIRCT2016122013194N3Hamedan University of Medical Sciences40
Recruiting
Phase 3
Assessment of effect of crocin on Covid-19 patientsCovid 19.COVID-19, virus identifiedU07.1IRCT20210203050233N1ational Institute for Medical Research Development (NIMAD)60
Recruiting
Phase 3
Evaluation effect of crocin in cardiac complication due to doxorubicin in patients with breast cancerIRCT20131017015044N5Mashhad University of Medical Sciences60
Recruiting
Phase 3
Therapeutic effect of crocin along with chemotherapy regimens in breast cancerBreast cancer.Malignant neoplasm of breast of unspecified siteC50.9IRCT20131017015044N3Mashhad University of Medical Sciences100